SHARONBIO

Savita Gowda has submitted to the Exchange vide letter dated October 17, 2013 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sharon Bio-Medicine Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended June 30,2013.

Sharon Bio-Medicine Limited has informed the Exchange vide its letter dated July 22, 2013 regarding "Setting up of Genotoxicity Laboratory at Taloja near Navi Mumbai".

Sharon Bio-Medicine Limited has informed the Exchange vide its letter dated June 11, 2013 regarding "SA- FORD - GLP Toxicology approval in ARGENTINA".

Sharon Bio-Medicine Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended March 31,2013.

Sharon Bio-Medicine Limited had informed the Exchange regarding approval from Bondholders for rollover of FCCB USD 16.50 Mn for another 5 years. The Company has now informed the Exchange that the said announcement should be read as follows:"The FCCB of USD 16.5 Million which had matured on December 04, 2012, which was further extended by bondholders till February 28, 2013, the bondholders have approved the restructuring proposal which involves extension of tenor of the existing Bonds for 5 years and issue of additional Bonds in lieu of the accrued interest till date. Accordingly, the Company h

Sharon Bio-Medicine Limited has informed the Exchange that the FCCB of USD 16.5 Million which had matured on December 04, 2012, which was further extended by bondholders till February 28, 2013 has been rolled over with the consent of bondholders for another 5 years. Accordingly, the Company have applied to Reserve Bank of India (RBI) as per the guidelines of ECB for their consent.

Sharon Bio-Medicine Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2012.

Sharon Bio-Medicine Limited has submitted to the Exchange a copy of the notice of the Extraordinary General Meeting of the members of the Company scheduled to be held on February 16, 2013.

Sharon Bio-Medicine Limited has informed the Exchange that :"Pursuant to our earlier intimation to the Stock Exchange on December 24, 2012 regarding extending the date for negotiation for conversion/ redemption or rollover of the Bonds which were due on December 04, 2012 to February 28, 2013, the board of directors at its meeting held today has resolved to convene an extra-ordinary general meeting to be held on February 16, 2013 for the approval of the shareholders on the said rollover of the existing FCCBs".

Sharon Bio-Medicine Limited has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the of the Company held on December 29, 2012.

Sharon Bio-Medicine Limited has informed the Exchange that the Annual General Meeting of the Members of the Company will be held on December 29, 2012.

Sharon Bio-Medicine Limited has informed the Exchange regarding "Extension date of FCCB"

Sharon Bio-Medicine Limited has informed the Exchange that the Register of Members and the Share Transfer Books of the Company will remain closed from January 07, 2013 to January 08, 2013 for the purpose of ascertaining eligibility of the members for entitlement of final dividend of Rs. 1.80/- per Equity Share of Rs. 10/- each.

Sharon Bio-Medicine Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended September 30,2012.

Sharon Bio-Medicine Limited has informed the Exchange that Board of Directors of the Company at the Meeting held on October 22, 2012 had resolved and recommended dividend @ Rs. 1.80 per share subject to approval of shareholders at the Annual General Meeting.

Mohan Kala has submitted to the Exchange vide letter dated September 18, 2012 a copy of disclosure under Regulation 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Mohan Prasad Kala has submitted to the Exchange vide letter dated September 08, 2012 a copy of disclosure under Regulation 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sharon Bio-Medicine Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2012.

Mohan Prasad Kala has submitted to the Exchange vide letter dated July 24, 2012 a copy of disclosure under Regulation 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

L&T Finance Limited has submitted to the Exchange vide its letter dated June 08, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sharon Bio-Medicine Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2012.

Sharon Bio-Medicine Limited has informed the Exchange vide its letter dated April 03, 2012, regarding "Subsidy/Financial Assistance of Rs. 690 Lacs from Development of Scientific and Industrial Research, Ministry of Science & Technology, New Delhi".

L&T Finance Limited has submitted to the Exchange vide its letter dated February 28, 2012 a copy of Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 release of pledged shares.

Mohan Prasad Kala has submitted to the Exchange a copy of disclosure under Regulation 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sharon Bio-Medicine Limited has informed the Exchange that Sharon Bio-Medicine Limited has filed its ANDA for Memantine Hydrochloride Tablets, 5mg and 10mg tablets form its drug product manufacturing facility at Silaqui, Dehradoon, Uttarakhand.

Sharon Bio-Medicine Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2011.

Mohan Prasad Kala has submitted to the Exchange a copy of disclosure under Regulation 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Ms. Savita Gowda has submitted to the Exchange a copy of Disclosure of Shareholding under Regulation 31(1) of SEBI Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Sharon Bio-Medicine Limited has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the of the Company held on December 19, 2011.

Sharon Bio-Medicine Limited has informed the Exchange that the Register of Members and the Share Transfer Books of the Company will remain closed from December 12, 2011 to December 19, 2011 for the purpose of ascertaining eligibility of the members for entitlemental of final dividend of Rs.1.80/- per Equity Share of Rs.10/- each and Annual General Meeting to be held on December 19, 2011.

Sharon Bio-Medicine Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on October 24, 2011, concluded the following:- (1) Recommendation of Dividend of Rs.1.80/- per share on 10556900 equity shares of Rs.10/- each fully paid up for the year ended June 30, 2011, subject to approval of the members at the ensuing Annual General Meeting.